MD Anderson and SNIPR BIOME join forces to advance new CRISPR-based microbiome therapeutics

The University of Texas MD Anderson Cancer Center and SNIPR BIOME today announced a strategic collaboration to advance new CRISPR-based microbiome therapeutics to reduce immune-related adverse events (irAE) in patients being treated with combined immune checkpoint inhibitors.

Generated by Feedzy